Galectin Therapeutics: Funding, Investors & Team (Sep 2026)

Galectin Therapeutics is applying its administration in galectin science and medication improvement to make new treatments for fibrotic illness and malignant growth. Drug competitors in light of the Company's remarkable starch innovation target galectin proteins which are key go betweens of biologic and pathologic capability. Galectin Therapeutics utilizes normally happening carb polymers with galactose deposits to make complex sugars with explicit atomic loads. Utilizing these novel starch based competitor intensifies that tight spot and repress galectin proteins, we are seeking after treatments for signs where galectins play a showed part in the pathogenesis of a specific illness. We center around sicknesses with serious, hazardous results to patients, and those where current therapy choices are restricted. Our methodology is to lay out clinical improvement moves toward that enhance the Company in the briefest time conceivable, and to look for accomplices as the program propels and requires a lot more noteworthy assets. Galectin Therapeutics influences broad logical and advancement ability as well as laid out associations with outside sources to accomplish savvy and productive turn of events. We are chasing after an unmistakable improvement pathway to clinical upgrade and commercialization for our lead intensifies in liver fibrosis and disease immunotherapy. Galectin Therapeutic stock is exchanged on the NASDAQ under the image GALT. The organization is situated in a suburb of Atlanta known as Norcross, Georgia USA

Galectin Therapeutics has raised $70.0M across 2 rounds on record. The most recent is an undisclosed round of $10.0M announced in Jul 2025.

Galectin Therapeutics' most recent funding round on record is an undisclosed round of $10.0M, announced in Jul 2025.

FundedIQ lists James Czirr (Founder) at Galectin Therapeutics.

Galectin Therapeutics is based in Norcross, Georgia, United States.

Galectin Therapeutics is in the 11-50 employee band.

Galectin Therapeutics' latest round of $10.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.